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were 32.3%, 22.0%, 13.9%, and 13.0%, respectively. These rates were similar to those 
in non-responders. Respondents with PBA symptoms (CNS-LS≥ 13) reported signifi-
cantly poorer HRQOL in all EQ-5D domains. Mean scores were worse for anxiety/
depression, pain/discomfort, and usual activities; 85% reported at least moderate 
pain or anxiety/depression; 50% reported at least moderate problems with usual 
activities. ConClusions: PBA symptoms assessed by either CNS-LS or the “invol-
untary episodes” question are prevalent among Veterans with TBI who responded 
to the survey. PBA symptoms were correlated with worse HRQOL.
PND46
Use Of Diary alarms ON electrONic Devices fOr cOllectiNg Data 
frOm migraiNe sUbjects With PhONOPhObia
Dallabrida S.M., Gary S.T.
PHT Corporation, Boston, MA, USA
objeCtives: Electronic Patient Reported Outcomes (ePRO) such as daily diaries 
are often used in migraine clinical trials to collect information regarding migraine 
frequency, duration, severity, and symptoms. In general, alarms are an effective 
tool for prompting subjects to complete diaries on schedule. However, 70-80% of 
migraineurs suffer from phonophobia during a migraine. Thus, it is possible that 
an alarm may worsen symptoms. To address this, a decibel meter was used to 
measure the sound level of alarms on three models of the PHT LogPad handheld 
electronic device, and readings were compared to published sound aversion thresh-
olds (SAT) for migraineurs. Methods: The LogPad (LW, CV and LV) models were 
placed at a distance of one or five feet from the decibel meter. Alarm sound was 
measured on two devices in triplicate at each sound setting. Results: The SAT 
for migraineurs is reported to be approximately 76 decibels (db) (ictal) and 91 db 
(interictal). Healthy subjects have a SAT of 105 db. When the LogPad LW and decibel 
meter were placed one foot apart, the decibel meter measured 58, 67, 75, and 83 
db at the normal, medium, high and very high sound settings, respectively, and 
measured 76 db for the CV and 80 db for the LV models. When any LogPad model 
was placed five feet away from the decibel meter, all readings were below the ictal 
SAT for migraineurs. ConClusions: Even at a 1 foot distance, the alarm volume 
on the LogPad LW can be set below the ictal SAT for migraineurs and is also above 
background sound. At a distance of 5 feet, all models tested are below SAT and 
above background. Therefore, the LogPad is a suitable handheld electronic device 
to use with migraineurs that suffer from phonophobia with alarm volumes that 
can be used below SAT.
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objeCtives: To describe the frequency and nature of patient-reported out-
come (PRO) conversations between physicians and patients with Cystic 
Fibrosis. Methods: A random sample of de-identified patients with Cystic 
Fibrosis in the United States was selected from a large de-identified database 
of medical office visit transcriptions. Transcriptions were based on physician-
dictated voice recordings detailing every individual patient encounter/visit. 
De-identified medical visit transcriptions were analyzed to evaluate the burden 
associated with Cystic Fibrosis, as depicted by PRO topics observed in patient-
physician dialog in the real-world practice setting. Descriptive statistics are 
reported. Results: 333 transcriptions of medical encounters between 130 phy-
sicians (most commonly pediatricians 11%, internists 10%, pulmonologists 8%, 
general practitioners 8%, and surgeons 8%) and 183 patients over a 2-year period 
were evaluated (patient mean age: 31yrs; 27% < 18yrs, male: 55%). Non-symptom 
related PROs, including quality of life and psychosocial impacts, were discussed 
by 50 patients (27%) (10% of patients < 18yrs, 34% of patients ≥ 18yrs); the most 
commonly reported concerns were related to anxiety (n= 16(9%)), depression 
(n= 14(8%)), ability to perform daily activities (n= 7(4%)), and work/school productiv-
ity (n= 6(3%)). Symptom-related PROs were discussed by 108 patients (59%) (52% of 
patients < 18yrs, 62% of patients ≥ 18yrs); the most commonly reported symptoms 
were cough (n= 51(28%)), difficulty breathing (n= 25(14%)), and difficulty gaining/
maintaining weight (n= 15(8%)). ConClusions: PROs, as a function of disease 
burden, were routinely discussed by patients with Cystic Fibrosis. PRO discussions 
were observed more frequently among adult patients than the pediatric patients, 
and symptom-related PROs were discussed more frequently than PROs related to 
quality of life and psychosocial impacts. Modalities to alleviate this patient burden, 
including appropriate therapeutic interventions, warrant scrutiny.
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objeCtives: The objectives of this study were to assess the quality of life and 
the determinants affecting QoL in children with epilepsy using Pediatric quality 
of life questionnaire (PedsQL). Methods: A prospective observational study was 
conducted at a public hospital. In these study children less than 18 years of age, 
diagnosed with epilepsy were included. HRQoL was assessed using PedsQL, which 
comprised of 23 questions related to physical, emotional, social and school func-
tioning. After getting consent, scale was administered to both parents and subjects 
separately. Multivariate logistic regression was done to assess the potential deter-
minants of low HRQoL scores. Results: A total of 270 children with epilepsy were 
included in this study. Mean age and mean duration of antiepileptic drug treat-
ment was found to be 11.2 years and 21.6±12 months respectively. Mean total score 
according to PedsQL was found to be 89.6±6.7 (Psychological subscale score 84.7±1.2, 
physical subscale score 94.4±5.9, emotional subscale score 85.6±16, social subscale 
score 94.7±9.9 and school subscale score 73.9±12.5). Long duration of antiepileptic 
objeCtives: Huntington’s disease (HD) is a rare neurodegenerative disease lead-
ing to sustained disability for patients and poor quality of life (QoL) for patients as 
well as caregivers. This study, conducted in US as a part of an international sur-
vey, investigated a disease-specific QoL instrument, the HD QoL Battery for Carers 
(HDQoL-C). Methods: The shortened version of the HDQoL-C comprised two 
components: the satisfaction with life (3 items) and the feelings about living with 
HD (17 items). Caregivers were asked to answer socio-demographic questions and 
complete the short version of the (HDQoL-C), a previously validated questionnaire. 
Item response could be chosen among 10 possibilities depending on frequency 
or intensity. Internal validity was evaluated through the factorial structure and 
internal consistency. External validation was tested using known-group compari-
son analyses between three severity subgroups (low, moderate, high), according 
to dependence, global clinical severity and motor severity. Results: The sample 
was composed of 361 family carers from US with 76% female, 16% single and 51 of 
average age. The majority of the caregivers represented the main caregivers of the 
HD patient (73%) and 61% of them lived with the HD patient. There were 2 items 
out of 20 with potential floor effects and 3 items with ceiling effects. Cronbach’s 
alpha coefficients ranged from 0.68 to 0.90 in the whole sample, indicating high 
internal consistency Analyses of the component of HDQoL-C dealing with the feel-
ings about living with HD, demonstrated satisfactory factor analysis. Known group 
analyses showed that the HDQoL-C scores were higher for carers who cared for 
patients in the low severity group than the two other groups, meaning that these 
carers had better QoL. ConClusions: The US shortened version of the HDQoL-C 
demonstrated good internal consistency and congruent validity when compared 
to the original English version.
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objeCtives: To examine seizure severity across treatment arms among clinical 
trial subjects with refractory partial-onset seizures (POS) who participated in a 
phase III clinical trial of eslicarbazepine acetate, a novel once-daily anticonvulsant 
recently approved for the adjunctive treatment of POS in adults. Methods: The 
Seizure Severity Questionnaire (SSQ), a validated instrument developed to evaluate 
the severity and bothersomeness of specific seizure characteristics, was adminis-
tered. The SSQ total score (TS) and domain scores of frequency and helpfulness of 
warning signs before seizures (BS), severity and bothersomeness of ictal movement 
and altered consciousness during seizures (DS), cognitive, emotional, and physical 
aspects of postictal recovery after seizures (AS), and overall severity and bother 
(SB) were calculated at baseline and at the end of maintenance therapy (12-week 
duration) from the per-protocol population. ANCOVA models, adjusted for baseline 
scores, estimated least square mean (LSM) differences between arms at the end of 
therapy. Results: Among 547 subjects, average age: 38.4, 63.3% Caucasian, 50.8% 
female, 70.4% (385) had TS results at baseline and at end-of-therapy. Among subjects 
receiving 1200 mg ESL, the TS LSM was significantly lower compared to placebo (2.80 
versus 3.29, p= 0.002); the LSMs were also significantly lower for DS (3.29 versus 
3.70, p= 0.032), AS (1.95 versus 2.51, p= 0.019), and SB (3.09 versus 3.65, p< 0.001), 
but not for BS. Among subjects treated with 800 mg ESL, the LSM differences vs. 
placebo for BS, DS, AS and TS did not achieve statistical significance. The SB LSM 
was significantly lower (3.28 versus 3.65, p= 0.013). ConClusions: In this post-
hoc analysis of a phase III trial, ESL-treated subjects had statistically-significantly 
lower SSQ total scores (1200 mg), less severity and bother during seizures (1200 mg), 
less cognitive, emotional and physical impact during postictal recovery (1200 mg), 
and lower overall levels of seizure severity and bother (1200 mg and 800 mg) than 
placebo-treated subjects.
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bACkgRound: PBA, characterized by uncontrollable episodes of crying and/or 
laughing, often exaggerated or inappropriate to the mood state, can occur in per-
sons with neurological disorders or injury of the brain. objeCtives: Compare PBA 
survey instruments and estimate prevalence of PBA symptoms and health-related 
quality of life (HRQOL) burden in Veterans with TBI. Methods: Cross-sectional 
survey with patient-level linkage to VA clinical data. OEF/OIF Veterans screening 
positive for TBI were mailed the seven-item Center for Neurologic Study-Lability 
Scale (CNS-LS) questionnaire with an initial question asking if the Veteran had 
“involuntary episodes of crying and/or laughing that were exaggerated or even 
contrary to how they felt at the time”. The EQ-5D, a standardized HRQOL ques-
tionnaire, was included. The presence of PBA symptoms was defined in this study 
as CNS-LS score≥ 13. The sensitivity of the “involuntary episodes” question was 
assessed against the CNS-LS. Results: The 4400 Veterans mailed surveys were 
predominantly male (95%); mean(SD) age 34(8.8) years. 728 Veterans returned sur-
veys. Among respondents, 60% answered “yes” to the “involuntary episodes” ques-
tion and 70% had CNS-LS≥ 13 (PBA symptoms). The ROC curve for the ‘involuntary 
episodes’ question indicates optimal sensitivity/specificity at CNS-LS score of 12. 
Comorbidities diagnosed in the CNS-LS≥ 13 population included: PTSD (53.4%), 
major depression (34.5%), headaches/migraine (20.0%) and anxiety disorders (20.4%); 
in contrast, prevalence for the same comorbidities among Veterans with CNS-LS< 13 
